Purpose FIAU, (1-(2′-deoxy-2′-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) has been used as a substrate for herpes simplex virus thymidine kinases (HSV-TK and HSV-tk, for protein and gene expression, respectively) and other bacterial and viral thymidine kinases for noninvasive imaging applications. Previous studies have reported the formation of a de-iodinated metabolite of 18 F-FIAU. This study reports the dynamic tumor uptake, biodistribution, and metabolite contribution to the activity of 18 F-FIAU seen in HSV-tk gene expressing tumors and compares the distribution properties with its de-iodinated metabolite 18 F-FAU. Methods CD-1 nu/nu mice with subcutaneous MH3924A and MH3924A-stb-tk+ xenografts on opposite flanks were used for the biodistribution and imaging studies. Mice were injected IV with either 18 F-FIAU or 18 F-FAU. Mice underwent dynamic imaging with each tracer for 65 min followed by additional static imaging up to 150 min postinjection for some animals. Animals were sacrificed at 60 or 150 min post-injection. Samples of blood and tissue were collected for biodistribution and metabolite analysis. Regions of interest were drawn over the images obtained from both tumors to calculate the time-activity curves. Results Biodistribution and imaging studies showed the highest uptake of 18 F-FIAU in the MH3924A-stb-tk+ tumors. Dynamic imaging studies revealed a continuous accumulation of 18 F-FIAU in HSV-TK expressing tumors over 60 min. The mean biodistribution values (SUV ± SE) for MH3924A-stb-tk+ were 2.07±0.40 and 6.15±1.58 and that of MH3924A tumors were 0.19±0.07 and 0.47±0.06 at 60 and 150 min, respectively. In 18 F-FIAU injected mice, at 60 min nearly 63% of blood activity was present as its metabolite 18 F-FAU. Imaging and biodistribution studies with 18 F-FAU demonstrated no specific accumulation in MH3924A-stb-tk+ tumors and SUVs for both the tumors were similar to those observed with muscle. Conclusion 18 F-FIAU shows a continuous accumulation of activity in HSV-TK expressing tumors.
Introduction
Fialuridine, [1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodouracil; FIAU] is a nucleoside analog and has been investigated as an antiviral agent for hepatitis B virus (HBV) infections [1, 2] . FIAU is a preferential substrate to several viral and bacterial thymidine kinases compared to mammalian thymidine kinase. This phenomenon has been utilized to study gene therapy with the reporter gene HSVtk [3] . FIAU labeled with radiolabeled iodine gained attention as a reporter probe for HSV-TK expression, and vector mediated gene expression has been successfully monitored in patients using 124 I-FIAU PET [4] . An overview of the analogs used for gene expression imaging has been briefly reviewed in the literature [5] . Recently, viral thymidine kinase (TK) based accumulation of 124 I-FIAU activity has been utilized for the detection of musculoskeletal bacterial infections [6, 7] . These new developments may open up new research avenues for the use of the more clinically favorable agent 18 F-FIAU. Our previous study described the biodistribution and metabolism of 18 F-FIAU in normal dogs [8] . 18 F-FIAU was metabolized in vivo resulting in 18 F-FAU. Generation of radioactive metabolites and their contribution to images may complicate the interpretation of results. A clearer understanding of the metabolite contribution to the images, in this particular case possible phosphorylation and trapping of 18 F-FAU by HSV-TK, requires further study. The interest in investigating the substrate specificity of HSV-TK for FAU is twofold: primarily to assess 18 F-FAU contribution as a metabolite to the 18 F-FIAU derived images and secondarily to further understand the activation of FAU. FAU was developed as an antineoplastic agent to take advantage of high thymidylate synthase (TS) levels observed in tumors resistant to fluorouracil (5FU) treatment. Once taken up in a cell, it was hypothesized that FAU may be phosphorylated by thymidine kinase to form FAU monophosphate. Then it will be methylated by TS to FMAU monophosphate. FMAU monophosphate will be further phosphorylated by nucleotide kinases and incorporated into DNA [9] . Initial in vitro thymidine kinase assay analysis showed FAU to be a poor substrate for mammalian thymidine kinase [10] . This, being a liability, led to exploring the activation of FAU by other nucleoside kinases to improve its therapeutic and/or imaging potential.
To address the substrate specificity of HSV-TK for FAU using a well-characterized HSV-tk stably expressing cell line, this study investigated (1) the in vitro substrate specificity of HSV-TK for FAU, (2) the dynamic uptake and biodistribution of 18 F-FIAU and 18 F-FAU in mice, and (3) the contribution of formed 18 F-FAU when 18 F-FIAU is used as a gene expression imaging agent.
Materials and methods

Materials
3 H-FAU (318.2 GBq/mmol, >99% radiochemical purity) and 14 C-FIAU (2.0 GBq/mmol, >99% radiochemical purity) were obtained from Moravek Biochemicals (Brea, CA, USA). 18 F-labeled FIAU and FAU were synthesized as described in the literature using 2,4-bis-O-(trimethylsilyl)-5-iodouracil and 2,4-bis-O-(trimethylsilyl)-uracil as intermediate precursors, respectively [11] . The total synthesis uncorrected yields varied between 10 and 12% with a specific activity of at least 111 GBq/μmol and purity >98%.
Cell lines and mouse model
The rat Morris hepatoma cell line (MH3924A) and MH3924A stably transfected with the HSV-tk gene (MH3924A-stb-tk+) were utilized [12] . Cell lines were maintained in RPMI-1640 medium (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum at 37°C in a humidified incubator with 5% CO 2 . Male CD-1 nu/nu mice (n=11/tracer), 6 to 8 weeks old, weighing between 28 and 30 g were purchased from Charles River Laboratories (Wilmington, MA, USA). All the experimental procedures using the animals were conducted according to protocols approved by the Animal Investigation Committee of Wayne State University. Mice were implanted subcutaneously with MH3924A and MH3924A-stb-tk+cells (1×10 6 cells/100 μl) in the right and left upper flanks, respectively. After inoculation, the tumor growth and animal weights were monitored three times a week. After 2 weeks, five and six animals were used for biodistribution for each tracer at 60 and 150 min, respectively. Of the six mice from the 150 min group, three mice underwent dynamic microPET imaging prior to biodistribution.
Uptake studies
Both cell lines were seeded at 2×10 5 cell/ml in 6-well plates. After 48 h, 50-60% confluent cells were incubated for 2 h with either 37 kBq/ml of 3 H-FAU or 1.85 kBq/ml of 14 C-FIAU. At the end of the incubation period, radioactive medium was removed and wells were refreshed with nonradioactive medium for 10 min to remove any nonphosphorylated compound. Then, the effluxed activity was removed and the plates were rinsed three times with icecold phosphate-buffered saline (PBS). The trypsinized cells were solubilized using 0.2 ml of soluene-350, mixed with 5 ml of ultima gold scintillation cocktail, and radioactivity measured for 5 min on a liquid scintillation counter (TriCarb, Packard Bioscience, Meriden, CT, USA). Experi-ments were done in triplicate and external standard quench correction was used during beta isotope counting. Data were represented as the percentage of incubated dose per 1×10 5 cells. To compare the selectivity between probes, accumulation ratios between HSV-TK and control cells for the same cell line (TK/control ratio) were calculated as a selectivity index [5] .
Biodistribution studies Animals were injected with either 18 F-FIAU or 18 F-FAU (mean activity: 4.29 MBq, range: 3.51-5.99) in 200 μl saline via a tail vein injection. At 60 (n=5) and 150 (n=6) min post-injection the animals were sacrificed, selected tissues were harvested and weighed, and activities were measured in a gamma spectrometer. If the tumor size was large, half the tumor was used to measure the radioactivity. The standard uptake values (SUVs) were calculated by dividing tissue radioactivity concentration (MBq/cc) by the injected radioactivity (MBq) per gram of body weight (assuming 1 cc=1 g) [13] . HPLC analysis of 60 min blood samples was performed to measure the metabolite concentration. For HPLC analysis, blood samples were processed mixing equal volumes of blood and 1 M perchloric acid (PCA), vortexed, and centrifuged at 14,000 g for 3 min. The supernatants were analyzed by HPLC using a C-18 column (Hypersil ODS, 250×4.6 mm) employing 10 mM sodium acetate in 6% acetonitrile at a flow rate of 1 ml/min.
In vivo imaging
To determine the dynamic uptake of FIAU and FAU in the tumors, animals were injected with either 18 F-FIAU or FAU (n=3 per tracer, mean activity: 4.29 MBq, range: 3.51-5.99) in 200 μl saline via a tail vein injection. The animals were induced with 3% and maintained at 1.5% of isofluorane throughout the experiment. Anesthetized mice were placed in the microPET scanner (Concorde Microsystems R4, Knoxville, TN, USA) in the supine position with the long axis of the animal parallel to the long axis of the scanner. With tumors near the center of the field of view (CFOV) dynamic imaging was performed from 5 to 65 min post-injection. At 65 and 120 min post-injection, emission scans of 10 min duration with two overlapping frames were acquired to obtain a whole-body image.
Image analysis
The listmode data were first sorted into sinograms, Fourier rebinned, and reconstructed using the ordered subset expectation maximization (OSEM 2D) algorithm. For reconstruction, a ramp filter was used with one half of the Nyquist frequency as the cutoff frequency. The dynamic image data were sorted into 21 frames with the time sequence: 9×60 s, 7×180 s, and 6×300 s. Circular regions of interest (ROIs) (∼radius: 8 mm) )covering the whole tumor were drawn on both the tumors to obtain the concentration of 18 F versus time. SUVs were calculated as described in the "Biodistribution studies" section. The decay corrected time activity values were averaged over three animals.
Statistical analysis
Statistical analysis of in vitro and in vivo studies was performed on Prism software (GraphPad, La Jolla, CA, USA) using an unpaired, two-tailed t test. For the comparison between HSV-TK positive and corresponding controls, p values < 0.05 were considered to be statistically significant.
Results
Cell incubation studies
Incubation studies performed over a 2-h time period demonstrated 34.5-fold (range: 27.4-39.7) and 25.5-fold (range: 24.8-26.5) higher accumulation of activity in the MH3924A-stb-tk+ expressing cell line compared to the control with FAU and FIAU, respectively (Table 1) . Even though the selectivity index of FAU is higher, the absolute accumulation is 100-fold less than that of FIAU suggesting a difference in phosphorylation by HSV-TK between the nucleosides.
Imaging and biodistribution studies with FIAU and FAU In 18 F-FIAU injected mice, tumor volumes were 422±164 and 472±181 mm 3 for MH3924A and MH3924A-stb-tk+ (p=0.57), respectively. Similarly, in 18 F-FAU injected mice, tumor volumes were 419±256 and 409±170 for MH3924A and MH3924A-stb-tk+ (p=0.97), respectively. The wholebody static images acquired at 65 and 120 min post-injection show a clear accumulation of activity in MH3924A-stb-tk+ tumors in 18 F-FIAU injected animals ( Fig. 1) . At both time points, activity in the control tumors was similar to that of muscle. Other organs with distinct contrast include gallbladder, kidneys, and bladder, where activity is accumulated due to clearance of the tracer. Time-activity curves generated from 5 min post-injection for over 60 min show a continuous accumulation of activity in the MH3924A-stb-tk+ tumors. In the control MH3924A tumors, the SUV activity levels were less than one and reached a plateau within 10 min of tracer administration (Fig. 2) .
In the case of 18 F-FAU, even though uptake of activity was observed in the MH3924A-stb-tk+ tumors, the absolute accumulation SUV values were less than one (HSV-TK vs control p≤0.19). The time-activity uptake of 18 F-FAU in the control MH3924A tumors was similar to that of 18 F-FIAU (Fig. 2) . Whole-body images acquired from mice injected with 18 F-FIAU and 18 F-FAU are shown in Fig. 1 . Biodistribution studies revealed, consistent with imaging, highest and significant uptake of activity in MH3924A-stb-tk+ tumors in 18 F-FIAU treated mice at both time points (HSV-TK vs control p≤0.007, Table 2 and Fig. 3) .
In 18 F-FAU injected mice, the MH3924A-stb-tk+ tumor (SUV ± SE: 0.72±0.09) activity was similar to that of control tumors (0.6±0.07) and muscle (0.56±0.05) at 60 min. At 150 min, there was a slight increase in accumulation of activity in the MH3924A-stb-tk+ tumor (1.01±0.09), but nonsignificant to control tumor (0.73± 0.08), muscle (0.59 ± 0.07), kidneys (0.97± 0.06), and spleen (1.0±0.09) ( Table 2 and Fig. 3 ). Blood activity levels at 60 and 150 min were less than that of tumors. At both time points, the activity in MH3924A-stb-tk+ tumors in 18 F-FIAU injected mice was two to four times higher than the FAU injected mice. The biodistribution of 18 F-FIAU and 18 F-FAU at both time points is presented in Table 2 .
HPLC analysis of blood samples of 18 F-FIAU injected mice at 60 min showed 37% (n=5, range: 25-58%) of activity in its native form with the primary metabolite as 18 F-FAU. In 18 F-FAU injected mice, greater than 95% (n=5, range: 93-98%) of activity is its native form. 
Discussion
Several studies have demonstrated the use of radiolabeled FIAU for HSV-tk gene expression imaging [14, 15] . The primary interest for this study was to investigate the dynamic uptake and biodistribution of 18 F-FIAU and assess the substrate specificity of HSV-TK for FAU and contribution of 18 F-FAU formed during the HSV-tk gene expression imaging with 18 F-FIAU as a reporter probe. Toward this goal, a well-characterized rat Morris hepatoma cell line stably expressing the HSV-tk gene (MH3924A-stb-tk+) under the CMV promoter was used for the experiments. The whole-body images acquired at 65 and 120 min postinjection showed a clear and specific accumulation of activity in the HSV-TK expressing tumors. At both time points, the activity in the control tumors was similar to that of background activity.
The time-activity curves acquired over 65 min showed a continuous accumulation activity in the MH3924A-stb-tk+ tumor. This is in contrast to the radioiodinated analog where accumulation of activity was observed within the first 15 min but did not increase after that [16] . It is possible that HSV-TK expression levels and specific activity of radiopharmaceuticals may lead to such differences. The effect of tumor size was ruled out as there was no statistically significant difference in tumor volumes between the control and genetically modified tumors. In the control tumors, the activity retention was found to be reaching a plateau within 10 min and at all times the SUV was close to or less than one. These results suggest that there are significant differences in accumulation at 120 min which may be due to a significant difference in phosphorylation rates of these two nucleosides.
HPLC analysis of blood samples from the mice studies showed 37% of 18 F-FIAU in the native form. The primary metabolite was identified as 18 F-FAU, making up about 63% of the blood activity. To account for the contribution of 18 F-FAU generated by de-iodination of 18 F-FIAU to the total uptake seen in the MH3924A-stb-tk+ tumors, micro-PET imaging and biodistribution studies with 18 F-FAU were pursued.
Static images acquired at 65 min post-injection of 18 F-FAU showed uniform accumulation of activity throughout the body other than kidneys, gallbladder, and bladder. The MH3924A-stb-tk+ to MH3924A activity ratio was 1.18 suggesting no specific phosphorylation and retention due to HSV-TK phosphorylated species. This is supported by time-activity curves over MH3924A-stb-tk+, which demonstrated a very slow accumulation of activity. Tissue analysis at 150 min showed a slight increase in MH3924A-stb-tk+ to MH3924A tumor activity ratio (1.45) in contrast to the cell culture uptake results, where the cells are continuously exposed to the substrate at an almost steadystate concentration in comparison to in vivo. The blood SUV values in 18 F-FAU injected mice at 60 and 150 min demonstrated less activity than both the tumors (Table 2) . So it is unlikely that the observed uptake is because of high blood activity. However, one can rationalize the high 18 F-FAU uptake observed due to phosphorylation by mammalian TK, a hypothesis conceived for its development. On the other hand, FIAU is a poor substrate to mammalian TK thus resulting in low background. Both these in vitro and in vivo results suggest that FAU is phosphorylated slowly in comparison to FIAU and there may be some transport differences between the nucleosides. This slow phosphorylation and accumulation of activity may be useful for therapeutic purposes since high levels of FAU can be maintained without much toxicity to normal tissue [17] .
With 18 F-FAU as a probe, no significant difference in uptake was observed between the MH3924A-stb-tk+ and control tumors. Considering that FIAU is metabolized slowly with variable de-iodination rates in mice, dogs, and humans at approximately 63, 22, and 1% (whole blood) [8, 18] at 60 min, respectively, the contribution of FAU formed to the activity seen in MH3924A-stb-tk+ tumors with FIAU as an imaging agent is minimal. It is possible that FAU phosphorylation rates may also be different. For example, in cells expressing Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK), reasonable FAU phosphorylation and accumulation of activity was demonstrated (Nimmagadda, unpublished data) . These data suggest that the affinity of HSV-TK for FAU is minimal even if pure FAU is used as an agent under a robust promoter biological model. Recent clinical studies showed positive identification of bacterial infections within 2 h post-injection of 124 I-FIAU [7] . These short incubation times are very favorable and may expand the role of 18 F-FIAU for infection imaging. However, FAU substrate specificity to other viral and bacterial thymidine kinases needs to be addressed before utilizing 18 F-FIAU as an imaging agent for infection imaging.
This study demonstrates that 18 F-FIAU accumulates preferentially and continuously over 60 min in HSV-TK expressing tumors. Studies using 18 F-FAU did not reveal any specific uptake of activity in HSV-TK expressing tumors, making it an unsuitable agent to image suicide gene expression. The contribution 18 F-FAU formed to the total uptake seen in HSV-TK positive tumors in 18 F-FIAU injected mice is minimal.
